JLJan L. C. Loeffen

Jan L. C. Loeffen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jan L. C. Loeffen has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    KMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage

    by Ingram Iaccarino, Alina M. Hartmann, Fatih Yalcin, Mayukh Mondal, Cecilia Bozzetti, Nadine Wolgast, Jan L. C. Loeffen, Judith M. Boer, Monika Brüggemann, Claudia D. Baldus, et al.

  • Open Access

    NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: a high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker

    by Emma Kroeze, Michelle M Kleisman, Lennart A Kester, Marijn A Scheijde-Vermeulen, Edwin Sonneveld, Jessica Gc Buijs-Gladdines, Melanie M Hagleitner, Friederike Ag Meyer-Wentrup, Margreet A Veening, Auke Beishuizen, et al.

    Twenty percent of children with T-cell lymphoblastic lymphoma (T-LBL) will relapse and have an extremely poor outcome. Currently, we can identify a genetically low-risk subgroup in pediatric T-LBL, yet these high-risk patients who need intensified or alternative treatment options remain undetected. Therefore, there is an urgent need to recognize these high-risk T-LBL patients through identification of molecular characteristics and biomarkers. By using RNA sequencing which was performed in 29/49 T-LBL patients who were diagnosed in the Princess Maxima Center for Pediatric Oncology between 2018-2023, we discovered a previously unknown high-risk biological subgroup of children with T-LBL. This subgroup is characterized by NOTCH1 gene fusions, found in 21% of our T-LBL cohort (6/29). All patients presented with a large mediastinal mass, pleural/pericardial effusions, and absence of blasts in the bone marrow, blood, and central nervous system. Blood CCL17 (C-C Motif Chemokine Ligand 17, TARC) levels were measured at diagnosis in 26/29 patients, and all six patients with NOTCH1 gene fusions patients exclusively expressed highly elevated blood CCL17 levels, defining a novel and previously not known clinically relevant biomarker for T-cell lymphoblastic lymphoma. Four out of these six patients relapsed during therapy, a fifth developed a therapy related acute myeloid leukemia during maintenance therapy. These data indicate that T-LBL patients with a NOTCH1 fusion have a high risk of relapse which can be easily identified using a blood CCL17 screening at diagnosis. Further molecular characterization through NOTCH1 gene fusion analysis offers these patients the opportunity for treatment intensification or new treatment strategies.

  • Open Access

    Constitutional 2p16.3 deletion including MSH6 and FBXO11 in a boy with developmental delay and diffuse large B-cell lymphoma

    by N. van Engelen, F. van Dijk, E. Waanders, A. Buijs, M. A. Vermeulen, J. L. C. Loeffen, R. P. Kuiper, M. C. J. Jongmans

    We describe a case of a boy with neurodevelopmental delay and a diffuse large B-cell lymphoma (DLBCL) in whom we discovered a germline de novo 2p16.3 deletion including MSH6 and part of the FBXO11 gene. A causative role for MSH6 in cancer development was excluded based on tumor characteristics. The constitutional FBXO11 deletion explains the neurodevelopmental delay in the patient. The FBXO11 protein is involved in BCL-6 ubiquitination and BCL-6 is required for the germinal center reaction resulting in B cell differentiation. Somatic loss of function alterations of FBXO11 result in BCL-6 overexpression which is a known driver in DLBCL. We therefore consider that a causative relationship between the germline FBXO11 deletion and the development of DLBCL in this boy is conceivable.


  • Age as a prognostic factor for outcome in patients (pts) with rhabdomyosarcoma (RMS)

    by J. C. van Gaal, W. T. van der Graaf, B. Rikhof, Q. C. van Hoesel, J. L. Loeffen, S. Sleijfer, E. S. de Bont

    10514 Background: RMS mainly affects children and adolescents and is rarely seen in adults. Survival of children with RMS increased dramatically during the last three decades because of the introduction of multiagent chemotherapy in clinical trials (5-yrs overall survival (OS) 73% nonmetastatic vs 24% metastatic disease). By contrast, the scarce data on adult RMS indicate a dismal outcome (reported 5- yrs OS 21–44%). The question is whether this is due to a more advanced stage at diagnosis and/or different histologic subtypes. Methods: Data were collected from RMS pts diagnosed in three Dutch University Medical Centres during 1977–2005. The influence of the prognostic factors on OS were analysed with Cox regression analysis. The estimated survival probabilities were calculated using the Kaplan-Meier with log-rank score. A p-value <0.05 was considered significant. Results: Data from 170 pts were successfully retrieved. Median age at diagnosis was 10 years (range 0–75 yrs). Five-yrs OS in pts <16 yrs was 63.2% versus 34.3% in pts ≥16 yrs (p<0.001). Age as a continuous variable significantly influenced OS in univariate and multivariate analysis (p=0.016 and p= 0.026 resp.). Five-yrs OS in the main histologic groups was highest for nonmetastatic Embryonal RMS (ERMS, 68.2%), followed by nonmetastatic Alveolair RMS (ARMS, 40.0%), and was worst in metastatic disease (11.5%). Unfavorable histologic subtypes were correlated with a higher age; median age ERMS 7.0 years, ARMS 16.0 (correlation coefficients 0.358, p<0.001) In ERMS, metastatic disease at presentation was correlated with higher age (p=0.005). In nonmetastatic ERMS (n=74) univariate and multivariate prognostic factors for OS were age (p=0.002 and p=0.023), IRSG Clinical Group (p=0.030 and p=0.005) and the use of chemotherapy (p<0.001 and p<0.001). Conclusions: Our study indicates that age as a continuous variable is of prognostic significance on survival in all RMS patients as well as in the main subgroup with nonmetastatic ERMS. Increasing age was correlated with advanced stage of disease in ERMS. Whether different biologic behaviour and/or a treatment effects contribute as well is subject of further study. No significant financial relationships to disclose.

  • Molecular characterization and mutational analysis of the human B17 subunit of the mitochondrial respiratory chain complex I

    by J. Smeitink, J. Loeffen, Roel Smeets, Ralf Triepels, W. Ruitenbeek, Frans Trijbels, L. van Den Heuvel

    Bovine NADH:ubiquinone oxidoreductase (complex I) of the mitochondrial respiratory chain consists of about 36 nuclear-encoded subunits. We review the current knowledge of the 15 human complex I subunits cloned so far, and report the 598-bp cDNA sequence, the chromosomal localization and the tissue expression of an additional subunit, the B17 subunit. The cDNA open reading frame of B17 comprises 387 bp and encodes a protein of 128 amino acids (calculated M r 15.5 kDa). There is 82.7% and 78.1% homology, respectively, at the cDNA and amino acid level with the bovine counterpart. The gene of the B17 subunit has been mapped to chromosome 2. Multiple-tissue dot-blots showed ubiquitous expression of the mRNA with relatively higher expression in tissues known for their high energy demand. Of these, kidney showed the highest expression. Mutational analysis of the subunit revealed no mutations or polymorphisms in 20 patients with isolated enzymatic complex I deficiency in cultured skin fibroblasts.